Literature DB >> 9786340

Tau protein pathology in neurodegenerative diseases.

M G Spillantini1, M Goedert.   

Abstract

Abundant tau-positive neurofibrillary lesions constitute a defining neuropathological characteristic of Alzheimer's disease. Filamentous tau pathology is also central to a number of other dementing disorders, such as Pick's disease, progressive supranuclear palsy, corticobasal degeneration and familial frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17). The discovery of mutations in the tau gene in FTDP-17 has firmly established the relevance of tau pathology for the neurodegenerative process. Experimental studies have provided a system for the assembly of full-length tau into Alzheimer-like filaments, providing an assay for the testing of compounds that inhabit the formation of tau filaments.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786340     DOI: 10.1016/s0166-2236(98)01337-x

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  143 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

2.  Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17.

Authors:  L Varani; M Hasegawa; M G Spillantini; M J Smith; J R Murrell; B Ghetti; A Klug; M Goedert; G Varani
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 3.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 4.  Protein aggregates and dementia: is there a common toxicity?

Authors:  S Lovestone; D M McLoughlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 5.  Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

Authors:  C Dingwall
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

6.  Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption.

Authors:  Emmalee M Jones; Manish Dubey; Phillip J Camp; Briana C Vernon; Jacek Biernat; Eckhard Mandelkow; Jaroslaw Majewski; Eva Y Chi
Journal:  Biochemistry       Date:  2012-03-14       Impact factor: 3.162

7.  Analysis of the exon 1 polymorphism in the Tau gene in transmissible spongiform encephalopathies.

Authors:  Raquel Sánchez-Valle; Pau Pastor; Jordi Yagüe; Teresa Ribalta; Francesc Graus; Eduardo Tolosa; Albert Saiz
Journal:  J Neurol       Date:  2002-07       Impact factor: 4.849

Review 8.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

9.  Multiple mechanisms of extracellular tau spreading in a non-transgenic tauopathy model.

Authors:  Meghan N Le; Wonhee Kim; Sangmook Lee; Ann C McKee; Garth F Hall
Journal:  Am J Neurodegener Dis       Date:  2012-11-25

Review 10.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.